利福昔明对比环丙沙星治疗急性肠炎临床研究

Evaluation of rifaximing versus ciprofloxaxin in the treatment of acute enterocolitis

目的 研究利福昔明对比环丙沙星治疗急性肠炎的有效性和安全性。 方法 采用随机对照方法 ,共治疗 5 1例急性肠炎。利福昔明治疗 2 5例 ,环丙沙星 2 6例 ,用药时间方法相同。观察治疗前后临床症状、大便性状、大便次数、便常规、血常规、尿常规及肝肾功能 ,以了解其疗效及不良反应情况。 结果 利福昔明组 (治疗组 )与环丙沙星组 (对照组 )相比 ,显效率分别为 92 .0 %和 80 .8% ,总有效率分别为 92 .0 %和 96 .2 % ,止泻时间治疗组 2 8.6 7± 15 .92h ,对照组 36 .12± 2 0 .70h ,均未见明显毒副作用。以上各项指标及两组在治疗过程中大便次数变化、大便常规复常率经统计学处理均无显著性差异 (P >0 0 5 )。 结论 利福昔明可用于治疗急性肠炎 ,与环丙沙星比较 ,疗效相仿 ,但耐受性好 ,口服不吸收 。

Objective To evaluate the efficacy and safety of rifaximing in the treatment of acute enterocolitis. Methods 51 patients with acute diarrhea were randomized divided into rifaximing group (25) and ciprofloxaxin group (26). Each group patients received either oral rifaximin 400 mg t.i.d.×1d and 400 mg b.i.d. ×2 d or oral ciprofloxacin 200 mg t.i.d. ×3 d.The clinical symptoms, form and frequency of stool were observed, the regular blood test, routine urine and stool examination, liver and kidney functions were taken. Results 92.0% of the patients in rifaximing group showed a significant improvement, compared with 80.8% in ciprofloxaxin group. The effective rate was 92.0% in rifaximing group, compared with 96.2% in ciprofloxaxin group. The times from starting until last unformed stool were 28.67±15.92 hours versus 36.12±20.70 hours. The adverse reactions of both groups were mild and uncommon. Conclusion Rifaximing was as effective and safe as ciprofloxacin for the treatment of acute enterocolitis. Because the former is virtually unabsorbed after oral administration, it is well tolerated.